力生制药：公司高管拟减持不超1.12万股公司股份

Core Viewpoint - The company, Lisheng Pharmaceutical, announced that senior management personnel Guo Xiaoyan plans to reduce holdings of the company's shares through centralized bidding, with a total reduction not exceeding 11,200 shares, which represents a maximum reduction of 0.0044% of the company's total share capital after excluding shares in the repurchase special account [1] Summary by Category - Company Announcement - Lisheng Pharmaceutical disclosed that Guo Xiaoyan intends to reduce her shareholding in the company [1] - The planned reduction is limited to a total of 11,200 shares [1] - The reduction accounts for a maximum of 0.0044% of the total share capital after excluding repurchased shares [1]